ESPR
NASDAQ · Pharmaceuticals
Esperion Therapeutics Inc
$2.55
-0.05 (-1.92%)
Financial Highlights (FY 2026)
Revenue
341.20M
Net Income
-53,118,891
Gross Margin
79.4%
Profit Margin
-15.6%
Rev Growth
+61.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 79.4% | 79.4% | 30.4% | 30.4% |
| Operating Margin | -0.2% | -0.1% | 33.0% | 36.5% |
| Profit Margin | -15.6% | -14.8% | 30.0% | 30.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 341.20M | 210.82M | 122.60M | 119.77M |
| Gross Profit | 270.78M | 167.31M | 37.28M | 36.42M |
| Operating Income | -545,917 | -303,587 | 40.47M | 43.73M |
| Net Income | -53,118,891 | -29,539,669 | 36.77M | 36.24M |
| Gross Margin | 79.4% | 79.4% | 30.4% | 30.4% |
| Operating Margin | -0.2% | -0.1% | 33.0% | 36.5% |
| Profit Margin | -15.6% | -14.8% | 30.0% | 30.3% |
| Rev Growth | +61.8% | +61.8% | -8.9% | +18.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 272.00M | 279.82M |
| Total Equity | — | — | 501.71M | 541.43M |
| D/E Ratio | — | — | 0.54 | 0.52 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -38,436 | -22,561 | 61.92M | 62.84M |
| Free Cash Flow | — | — | 30.39M | 39.08M |